Vericel (VCEL) Competitors $35.71 -0.18 (-0.50%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. LEGN, RVMD, RYTM, RNA, NUVL, AXSM, CRSP, ABVX, MRUS, and CYTKShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Abivax (ABVX), Merus (MRUS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Its Competitors Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics Abivax Merus Cytokinetics Vericel (NASDAQ:VCEL) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer VCEL or LEGN? In the previous week, Legend Biotech had 8 more articles in the media than Vericel. MarketBeat recorded 17 mentions for Legend Biotech and 9 mentions for Vericel. Vericel's average media sentiment score of 1.31 beat Legend Biotech's score of 1.19 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, VCEL or LEGN? Vericel has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$237.22M7.60$10.36M$0.12297.58Legend Biotech$627.24M10.05-$177.03M-$0.88-38.99 Which has more risk and volatility, VCEL or LEGN? Vericel has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Is VCEL or LEGN more profitable? Vericel has a net margin of 2.85% compared to Legend Biotech's net margin of -40.83%. Vericel's return on equity of 2.47% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Vericel2.85% 2.47% 1.69% Legend Biotech -40.83%-32.00%-20.07% Do analysts prefer VCEL or LEGN? Vericel presently has a consensus target price of $60.40, indicating a potential upside of 69.14%. Legend Biotech has a consensus target price of $74.22, indicating a potential upside of 116.33%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Do institutionals and insiders believe in VCEL or LEGN? 70.9% of Legend Biotech shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryVericel beats Legend Biotech on 10 of the 16 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$3.06B$5.75B$9.85BDividend YieldN/A2.26%3.95%4.02%P/E Ratio296.6921.1531.3126.63Price / Sales7.60383.94459.79120.56Price / Cash116.6444.4437.7659.36Price / Book5.878.0810.026.70Net Income$10.36M-$54.08M$3.27B$265.68M7 Day Performance0.76%2.44%3.26%3.46%1 Month Performance-13.85%3.56%4.45%1.11%1 Year Performance-32.07%18.78%44.34%24.00% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel2.3816 of 5 stars$35.71-0.5%$60.40+69.1%-33.0%$1.80B$237.22M296.69300Positive NewsLEGNLegend Biotech3.8986 of 5 stars$37.45-0.1%$72.38+93.3%-39.1%$6.89B$627.24M0.002,609News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.3218 of 5 stars$36.45+0.4%$69.54+90.8%-12.7%$6.79B$11.58M0.00250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.5242 of 5 stars$98.09+0.5%$101.57+3.5%+115.7%$6.48B$130.13M0.00140Positive NewsInsider TradeRNAAvidity Biosciences2.9798 of 5 stars$44.48-4.3%$67.00+50.6%+9.4%$5.98B$10.90M0.00190Positive NewsNUVLNuvalent3.4383 of 5 stars$75.01-1.4%$119.60+59.4%-9.7%$5.48BN/A0.0040News CoveragePositive NewsAXSMAxsome Therapeutics4.7772 of 5 stars$111.13+1.8%$178.00+60.2%+37.0%$5.45B$385.69M0.00380News CoveragePositive NewsInsider TradeCRSPCRISPR Therapeutics3.5205 of 5 stars$57.59-3.6%$71.60+24.3%+11.0%$5.43B$37.31M0.00460Positive NewsAnalyst UpgradeABVXAbivax2.7265 of 5 stars$70.01-0.6%$92.33+31.9%+564.1%$5.32BN/A0.0061News CoveragePositive NewsAnalyst RevisionMRUSMerus2.3295 of 5 stars$66.00-1.9%$88.50+34.1%+26.9%$5.09B$36.13M0.0037News CoveragePositive NewsAnalyst ForecastCYTKCytokinetics3.7418 of 5 stars$38.95+0.7%$71.58+83.8%-32.3%$4.63B$18.47M-7.64250News CoveragePositive News Related Companies and Tools Related Companies LEGN Competitors RVMD Competitors RYTM Competitors RNA Competitors NUVL Competitors AXSM Competitors CRSP Competitors ABVX Competitors MRUS Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access